Open Heart

JANUARY 8, 2024

Background A quarter of patients with severe aortic stenosis (AS) were asymptomatic, and only a third of them survived at the end of 4 years. We intended to study the effect of early AVR (eAVR) in this subset of asymptomatic patients with preserved left ventricle function. The primary outcome was all-cause mortality.

Aortic valve 98

Aortic valve Aortic Preserved Ejection Fraction Stenosis 98

DAIC

FEBRUARY 29, 2024

24: Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials (Session 402) Saturday, April 6 9:30 – 10:30 a.m.

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

Cardiology Update

APRIL 9, 2024

EMPACT-MI 1 ( NCT04509674 ) studied the effects of empagliflozin in patients who have experienced myocardial infarction (MI). SMART 4 ( NCT04722250 ) studied patients with severe aortic stenosis and a small aortic annulus who underwent transcatheter aortic valve replacement (TAVR). Here is our curated list of the top sessions.

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52

Cardiometabolic Health Congress

NOVEMBER 14, 2024

Emerging Risk Factors: Non-traditional factors such as the microbiome, pollution, and somatic mutations are increasingly linked to “SMuRFless” myocardial infarction (MI) cases. High Lp(a) is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD), aortic stenosis, and all-cause mortality.

CME 103

CME Obesity Heart Failure Biomarkers 103